154 related articles for article (PubMed ID: 1450043)
1. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
Thürlimann B; Waldburger R; Senn HJ; Thiébaud D
Ann Oncol; 1992 Sep; 3(8):619-23. PubMed ID: 1450043
[TBL] [Abstract][Full Text] [Related]
2. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
Ostenstad B; Andersen OK
Acta Oncol; 1992; 31(8):861-4. PubMed ID: 1290634
[TBL] [Abstract][Full Text] [Related]
3. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
4. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.
Zojer N; Keck AV; Pecherstorfer M
Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
[TBL] [Abstract][Full Text] [Related]
6. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
7. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
8. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
[TBL] [Abstract][Full Text] [Related]
10. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
11. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell AJ; Markham A
Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
[TBL] [Abstract][Full Text] [Related]
12. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
[TBL] [Abstract][Full Text] [Related]
13. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
[TBL] [Abstract][Full Text] [Related]
14. Conventional treatment of hypercalcemia of malignancy.
Davidson TG
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S8-15. PubMed ID: 11757206
[TBL] [Abstract][Full Text] [Related]
15. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.
Dodwell DJ; Howell A; Morton AR; Daley-Yates PT; Hoggarth CR
Postgrad Med J; 1992 Jun; 68(800):434-9. PubMed ID: 1437922
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure.
Davenport A; Goel S; Mackenzie JC
Scand J Urol Nephrol; 1993; 27(4):447-51. PubMed ID: 8159916
[TBL] [Abstract][Full Text] [Related]
18. One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancy.
Sawyer N; Newstead C; Drummond A; Newland A; Cunningham J
Clin Lab Haematol; 1989; 11(3):179-84. PubMed ID: 2591149
[TBL] [Abstract][Full Text] [Related]
19. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
20. A dose-finding study of zoledronate in hypercalcemic cancer patients.
Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
